[1]刘萍△.依托泊苷胶囊联合沙利度胺维持治疗广泛期小细胞肺癌效果观察[J].郑州大学学报(医学版),2013,(03):401.
 LIU Ping.Efficacy of etoposide plus thalidomide for maintenance treatment of extensive small cell lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(03):401.
点击复制

依托泊苷胶囊联合沙利度胺维持治疗广泛期小细胞肺癌效果观察
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2013年03期
页码:
401
栏目:
应用研究
出版日期:
2013-06-20

文章信息/Info

Title:
Efficacy of etoposide plus thalidomide for maintenance treatment of extensive small cell lung cancer
作者:
刘萍
郑州大学第二附属医院肿瘤科 郑州 450014
Author(s):
LIU Ping
Department of Oncology, the Second Affiliated Hospital,Zhengzhou University, Zhengzhou 450014
关键词:
小细胞肺癌依托泊苷沙利度胺维持治疗
Keywords:
small cell lung canceretoposidethalidomidemaintenance treatment
分类号:
R734.2
摘要:
摘要目的:观察依托泊苷胶囊联合沙利度胺用于广泛期小细胞肺癌(EDSCLC)维持治疗的效果。方法:90例EDSCLC患者接受6周期的顺铂联合依托泊苷(EP)方案化疗,病情控制。然后分为观察组45例和对照组45例。观察组给予依托泊苷胶囊100 mg/d,口服,第1~10天,3周为1个周期;沙利度胺100 mg/d,连续睡前顿服。2组每2个月复查直至疾病进展。结果:2组KaplanMeier生存曲线差异有统计学意义(χ2=11.653,P=0.001)。观察组中位无进展生存期为5.6个月(95%CI=4.8~6.4个月),对照组为4.2个月(95%CI=3.7~4.7个月),观察组中位无进展生存期较对照组延长了1.4个月。观察组不良反应主要为骨髓抑制、消化道反应、嗜睡及便秘,多为轻度反应,经对症治疗后缓解。结论:依托泊苷胶囊联合沙利度胺用于EDSCLC的维持治疗效果较好。
Abstract:
AbstractAim: To observe the clinical efficacy of etoposide plus thalidomide for maintenance treatment of extensive small cell lung cancer (EDSCLC). Methods: A total of 90 patients diagnosed as EDSCLC received 6 cycles of standard chemotherapy,and obtained disease control.Then they were divided into two groups and 45 cases in each group.Treatment group received etoposide plus thalidomide for maintenance treatment(etoposide 100 mg/d, per os,Day 1-10, every 21 days was a cycle; thalidomide 100 mg/d, per os, one single dose before sleep). The control group did not receive any intervention.Regular observations and followup were performed in both groups. Results: The KaplanMeier survival curves of the two groups were significantly different(χ2=11.653,P=0.001).The median progressionfree survival for treatment group and control group was 5.6 months (95%CI=4.8-6.4 months) and 4.2 months (95%CI=3.7-4.7 months).The side effects of treatment group included bone marrow suppression, gastrointestinal reactions, sleepiness and constipation, which relieved after drug withdrawal and symptomatic support therapy. Conclusion: Etoposide plus thalidomide for maintenance treatment of EDSCLC have better effect.

参考文献/References:

[1]Kelly K. New chemotherapy agents for small cell lung cancer[J]. Chest, 2000, 117(4 Suppl 1):156S
[2]Jokman DM, Johnson BE. Small cell lung cancer[J].Lancet, 2005,366(9494):1385
[3]吴国明,林克雄. 晚期非小细胞肺癌维持治疗的研究进展[J].西部医学,2010,22(4):589
[4]Rowe TC, Tewey KM, Liu LF. Identification of the breakagereunion subunit of T4 DNA topoisomerase[J]. J Biol Chem,1984,259(14):9177
[5]孔雁,董倩,姜达. 沙利度胺治疗实体瘤的研究新进展[J].现代肿瘤医学,2010,18(8):1665
[6]Miched Delforge,庄俊玲.多发性骨髓瘤治疗策略进展[J].中国实用内科杂志,2012,32(3):163
[7]王彩玲,王俊生.IP方案联合沙利度胺二线治疗晚期非小细胞肺癌的临床观察[J].实用癌症杂志,2011,26 (1):89
[8]Pujol JL,Breton JL,Gervais R,et al.PhaseⅢdoubleblind,placebocontrolled study of thalidomide in extensivedisease smallcell lung cancer after response to chemotherapy:an intergroup study FNCLCC leo04IFCT0001[J]. J Clin Oncol, 2007, 25(25):3945

相似文献/References:

[1]李向玉),潘徐彪),魏 楠),等.以眼部为首发症状的小细胞肺癌一例并文献复习[J].郑州大学学报(医学版),2019,(01):141.[doi:10.13705/j.issn.1671-6825.2018.04.025]

备注/Memo

备注/Memo:
△女,1971年11月生,硕士,副主任医师,研究方向:恶性肿瘤的防治
更新日期/Last Update: 2013-07-03